NCT04436029View on ClinicalTrials.gov

Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

February 18, 2022

Study Completion Date

April 9, 2022

Conditions
Multiple Myeloma
Interventions
BIOLOGICAL

Descartes 11

Car T-cells

Trial Locations (4)

20817

Center for Cancer and Blood Disorders, Bethesda

53226

Medical College of Wisconsin, Madison

73104

Stephenson Cancer Center Oklahoma University Health Science Centers, Oklahoma City

07601

Hackensack University Medical Center, Hackensack

Sponsors
All Listed Sponsors
lead

Cartesian Therapeutics

INDUSTRY